Safety of Bisphosphonates To Be Reviewed By FDA Advisory Committees
This article was originally published in The Pink Sheet Daily
The Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees will meet Sept. 9 to review the safety of long-term use of bisphosphonates in treating osteoporosis.
You may also be interested in...
FDA revises topics for September committee two weeks after announcing the meeting.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.